Although the cerebrospinal fluid (CSF) biomarkers Aβ1–42, T-tau and P-tau181P have an added diagnostic value for differential dementia diagnosis, concomitant amyloid pathology in DLB limits the use of CSF Aβ1–42 for discriminating DLB from AD (Slaets et al., 2013). This evidence concerns the gene MAPT and Lewy body dementia.